All In Biotech

Drug Trial Radar · NCT07030478

A Study to Evaluate the Safety and Tolerability of EP0089

A Phase I/IIa Study to Evaluate the Safety and Tolerability of Monoclonal Antibody EP0089 in Patients With Advanced Solid Tumours

Last checked: Nov 19, 2026Latest source record: Jun 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

190

Planned (sponsor's estimate)

Start

Sep 2025

Primary completion

Mar 2028

Study completion Jun 2029

Sponsor

Lead sponsor
Ellipses PharmaIndustry
Sponsor type
Industry
First posted
Jun 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human (FIH), first-in-class, Phase I/IIa, open-label study designed to evaluate the safety and tolerability of EP0089 (study drug). Study drug will initially be given via intravenous (IV) infusion once every 2 weeks (Q2W), with one treatment cycle defined as 14 days. The study will enroll patients with advanced solid tumours for whom no standard therapy exists or for whom standard therapy has failed. An independent Safety Monitoring Committee (SMC) will review safety data at regular intervals to ensure participant safety and support dose escalation decisions.

Conditions

  • Solid Cancers
  • Solid Tumours

Interventions

  • EP0089-101Drug

    EP0089 will be initially administered by intravenous (IV) infusion once every 2 weeks (Q2W)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability of EP0089Time frame: 126 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.